ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0381

Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies

Safoah Agyemang1, Melicent Miller1, Tori Justin2, Lydia Oberholtzer2 and Joy Buie1, 1Lupus Foundation of America, Washington, DC, 2Sharp Insight LLC, Montgomery County, MD

Meeting: ACR Convergence 2025

Keywords: clinical trial, Disparities, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The purpose of Research Accelerated by You (RAY) is to amplify awareness about clinical research and trials and ensure lupus patient partnership in therapeutic development. However, Black/ African Americans (B/AA) make up only 16% of RAY participants, a notable disparity as B/AAs account for 30-43% of the lupus population. To address the lack of representativeness in race/ethnicity amongst B/AA in RAY, we explored B/AA motivations and communications preferences driving registry enrollment decision-making.

Methods: We conducted two focus groups with people living with lupus (PWL) who were already enrolled in RAY or a part of the Lupus Research Action Network (LRAN), a patient peer-to-peer network, but not enrolled in RAY. All focus group (FG) participants were B/AA females aged 25-46 years (n=4 each). Key informant (KI) interviews were also conducted with PWL with no affiliation with the Lupus Foundation of America (LFA)(n=1) and registry directors at academic medical centers (n=3). Audio-recordings were transcribed and cleaned using Otter.ai. Manual content analysis followed an inductive approach, allowing themes to emerge from data rather than predetermined categories for FGs and KIs. Resulting themes with exemplary quotes are presented in Tables 1-4.

Results: Three overarching themes emerged:1.Communication Preferences: Participants receive most of their lupus information from the LFA’s emails, social media, and website, in addition to email/text alerts from other research institutions. Furthermore, some participants also noted that their family members/friends have sent them lupus materials; however, most shared they prefer to receive lupus-related information from their healthcare team. 2.Building Trust and Rapport: KIs mentioned this theme as essential to encouraging registry and clinical trial enrollment. To build rapport, KIs discussed the importance of speaking with patients face-to-face about enrollment, educating potential participants about patient protections, and explaining the history of mistrust as it relates to the medical profession and the B/AA community in the U.S. 3.Curating Messages/Imagery that Resonate: After reviewing RAY marketing materials, participants stated models who look indisputably like the target audience (i.e., B/AA PWL) are preferred. Additionally, some participants mentioned they prefer the models to feature lupus symptoms such as having a “rash” or “swelling around the eyes.” Participants preferred messaging demonstrating how RAY benefited the patient rather than the researcher, and they favored clear and straightforward content. To improve messaging, participants suggested avoiding the notion that lupus is “easy” and adding language centering the target population.

Conclusion: B/AA PWL may be more inclined to enroll in registries and clinical trials if they receive clear and transparent information from their healthcare team about the benefits and risks of participation, particularly as they relate to B/AA PWL. Centering the experience of B/AA PWL in registry and clinical communication materials is a key theme of importance to potential study participants and may improve enrollment in the registry.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Agyemang: None; M. Miller: None; T. Justin: None; L. Oberholtzer: None; J. Buie: Bristol-Myers Squibb(BMS), 1, Fate Therapeutics, 1, Genentech, 1, Novartis, 1.

To cite this abstract in AMA style:

Agyemang S, Miller M, Justin T, Oberholtzer L, Buie J. Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/improving-participation-in-the-lupus-foundation-of-americas-research-accelerated-by-you-ray-patient-registry-by-understanding-patient-preference-in-communication-strategies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-participation-in-the-lupus-foundation-of-americas-research-accelerated-by-you-ray-patient-registry-by-understanding-patient-preference-in-communication-strategies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology